Market Exclusive

Analyst Activity – Scotiabank Raises Its Price Target On Cara Therapeutics (NASDAQ:CARA) to $31.50

Analyst Ratings For Cara Therapeutics (NASDAQ:CARA)

Today, Scotiabank raised its price target on Cara Therapeutics (NASDAQ:CARA) to $31.50 per share.

There are 2 hold ratings, 9 buy ratings on the stock.

The current consensus rating on Cara Therapeutics (NASDAQ:CARA) is Buy (Score: 2.82) with a consensus target price of $26.63 per share, a potential 113.34% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics (NASDAQ:CARA) has insider ownership of 7.50% and institutional ownership of 61.13%.

Recent Trading Activity for Cara Therapeutics (NASDAQ:CARA)
Shares of Cara Therapeutics closed the previous trading session at with shares trading hands.

Exit mobile version